期刊文献+

晚期小鼠肺癌模型对益气养阴清热方及化疗反应的研究 被引量:2

Study on establishing mice model of advanced lung cancer bearing Lewis lung carcinoma
原文传递
导出
摘要 目的:建立晚期肺癌的动物模型,研究其对化疗药物及益气养阴清热方的治疗反应状况,寻找适合评价以控制症状、改善生活质量为目的疗法的实验模型。方法:通过胸腔移植的方法建立晚期肺癌的动物模型,研究该模型的生存期及对氟尿嘧啶(20mg/kg)、顺铂(3mg/kg)、益气养阴清热方浓缩中药溶液(28.6mg/kg)的治疗反应状况,用免疫组化的方法检测了肿瘤组织内表皮生长因子(EGF)和表皮生长因子受体(EGFR)等蛋白表达(400×),分析了该模型较皮下移植模型的优势。结果:经过治疗后,胸腔组内的中药组、顺铂组体重下降程度较对照组和氟尿嘧啶组体重下降程度低(P<0.05)。皮下组内各小组体重变化无明显差异。胸腔组较相应皮下组饲料消耗量少。胸腔组内的对照组和氟尿嘧啶组饲料消耗量较其他组明显减少(P<0.05),益气养阴清热方组、顺铂组间无明显差异。皮下组内各小组饲料消耗量无明显差异。对照组和氟尿嘧啶组中EGF、EGFR阳性细胞数较其他组明显增多。结论:胸腔移植模型可作为晚期肺癌动物模型,胸腔移植模型较皮下移植模型能更好地反映药物的作用,化疗药物、益气养阴清热方对EGF、EGFR等的表达有不同程度的抑制作用,益气养阴清热方对抑制肿瘤发展优势不明显,但对改善模型生存时间、生活状态有较好的作用。 Objective: To find a nice animal model for evaluating the therapy of controlling the symptoms and improving the quality of life. Meth- ods: ( I ) Model: The C5 BL/6 mice were divided into two groups: subcutaneous implant group and thoracic cavity implant group. The sub- culturing Lewis lung cancer cells were implanted into thoracic cavity or armpit of mice to make models. (2) Group: Subcutaneous implant group and thoracic cavity implant group were respectively divided into five groups randomly: ~'~k=]~ ~ group, DDP group and control group. Each group contained twenty mice. Four drugs were injected into four chemotherapy groups on the 6th day and the 11 th day of building mod- els respectively. (4) Quality of Life : The weight of the mice and the consumption of feed were measured at 8:00-9:00 p.m. everyday. The expressions of EGF and EGFR in the lung cancer tissue were examined by immunohistochemical method. Results: ( 1 ) Quality of life : (~ Weight: The weight of thoracic cavity implant group was significantly lower than that of subcutaneous implant group. In thoracic cavity im- plant group, the weight of control group and of ~p'~l^ll)~ group were both obviously lower than those of other groups (P 〈0.05). But there were no significantly differences in the weight of subcutaneous implant group. (~)Consumption of feed : The feed consumption of thoracic cavity implant group was significantly less than that of subcutaneous implant group. In thoracic cavity implant group, the feed consumptions of the control group and of ~/~II~ group were both apparently less than those of other groups (P 〈 0.05 ). But there were no significantly differ- ences in the weight of subcutaneous implant group. (2) IHC: The expression of EGF and of EGFR in DDP group were both significantly less than those in other groups ( P 〈 0.05 ). Conclusions: Thoracic cavity implant model in responding to the therapeutic efficacy was superior to subcutaneous implant model. Different drugs inhibited the expression of EGR and EGFR. Traditional Chinese medicine had no obvious advantage supressing the development of tumour, but it could prolongate survival time and improve life in our model.
出处 《中药药理与临床》 CAS CSCD 北大核心 2012年第4期98-102,共5页 Pharmacology and Clinics of Chinese Materia Medica
关键词 益气养阴清热方 化疗 晚期肺癌 胸腔移植模型(胸腔组) 皮下移植模型(皮下组) traditional chinese medicine chemotherapy advanced lung cancer thoracic cavity implant model subcutaneous implant mod- el quality of life (QoL)
  • 相关文献

参考文献10

二级参考文献12

  • 1李家泰.临床药理学(第二版)[M].北京:人民卫生出版社,1998.818.
  • 2[1]Nakamura K, Hanibuchi M, Yano S et al. Apoptosis induction of human lung cancer cell line in multicellular heterospheroids with humanized antiganglioside GM2 monoclonal antibody [J]. Cancer Res, 1999;59(20):5323-5330.
  • 3[2]Chee JJ, Peck K, Hong TM et al. Global analysis of gene expression in invasion by a lung cancer model [J]. Cancer Res, 2001; 61(13):5223-5230.
  • 4[3]Johnston MR, Mullen JB, Pagura ME et al. Validation of an orthotopic model of human lung cancer with reginal and systemic metastases [J]. Ann Thorac Surg, 2001; 71(4):1120-1125.
  • 5[4]Yamaura T, Doki Y, Murakami K et al. Model for mediastinal lymph node metastasis produced by orthotopic intrapulmonary implantation of lung cancer cells in mice [J]. Human Cell, 1999;12(4):197-204.
  • 6[5]DeVita VT Jr. The relationship between tumor mass and resistance to chemotherapy. Implications for surgical adjuvant treatment of cancer[J]. Cancer, 1983;51(7):1209-20
  • 7[6]Yamamura Y, Nakajima T, Ohta K, Nashimoto A, Arai K, Hiratsuka M, et al. Determining prognostic factors for gastric cancer using the regression tree method[J]. Gastric Cancer, 2002; 5(4): 201-7
  • 8[7]Van Laar JA, Rustum YM, Van der Wilt CL, Smid K, Kuiper CM, Pinedo HM, et al. Tumor size and origin determine the antitumor activity of cisplatin or 5-fluorouracil and its modulation by leucovorine in murine colon carcinomas[J]. Cancer Chemother Pharmacol,1996;39(1-2):79-89
  • 9[8]Milas L, Ito H, Hunter N. Effect of tumor size on S-2-(3-aminopropy lamino)ethylphorothioic acid and misonidazole alteration of tumor respose to cyclophosphamide[J]. Cancer Res,1983;43(7):3050-6
  • 10[9]Wenger FA, Jacobi CA, Zieren J, Docke W, Volk HD, Muller JM. Tumor size and lymph-node status in pancreatic carcinoma is there a correlation to the preoperative immune function[J]. Langenbecks Arch Surg, 1999;384(5):473-8

共引文献31

同被引文献18

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部